Open AccessHigh BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules
Author(s) -
Xingjia Li,
Xiaodong Mao,
Guofang Chen,
Qifeng Wang,
Xiaoqiu Chu,
Xin Hu,
Wenbo Ding,
Zheng Zeng,
Jianhua Wang,
Shuhang Xu,
Chao Liu
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000016343
Subject(s) - medicine , thyroid nodules , thyroid carcinoma , mutation , thyroid , indeterminate , thyroidectomy , mutation testing , radiology , pathology , cytology , gastroenterology , biology , biochemistry , mathematics , pure mathematics , gene
To estimate the BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma (PTC), and the diagnostic value of BRAFV600E mutation status in thyroid nodules with indeterminate TBSRTC categories. A total of 4875 consecutive samples for thyroid ultrasound-guided fine-needle aspiration cytology (FNAC) and BRAF V600E mutation analysis were collected from patients at Jiangsu Province Hospital on Integration of Chinese and Western Medicine. Among all the cases, 314 underwent thyroidectomy. According to TBSRTC categories, FNAC was performed for a preoperative diagnosis. ROC of the subject was constructed to evaluate the diagnostic value of these 2 methods and their combination. BRAF V600E mutation in FNAC of thyroid nodules occurred in 2796 samples (57.35%). Of 353 nodule samples from 314 patients with thyroid operation, 333 were pathologically diagnosed as PTC. Of these PTC patients, 292 (87.69%) were found to have BRAF V600E mutation in their preoperative FNAC. In 175 cytologically indeterminate thyroid nodules, BRAF V600E mutation identified 88% of PTC. According to ROC data, BRAF V600E mutation testing had an obviously higher sensitivity (87.69%) and specificity (100.00%) than TBSRTC. Combining BRAF V600E mutation testing and TBSRTC achieved the largest AUC (0.954). For 41 PTC with a negative BRAF V600E mutation in preoperative evaluation, the repeated BRAF V600E mutation testing found out 12 samples with BRAF V600E mutation. The true BRAF V600E mutation rate of Chinese PTC patients was 91.29%. Chinese patients with PTC have a higher frequency of BRAF V600E mutation. The BRAF V600E mutation testing affords a high diagnostic value in thyroid nodules with indeterminate cytology.